Jaguar Health announces press release on crofelemer compassionate use for infant MVID patient in EU
JAGX•Press release on crofelemer compassionate use in EU infant patient
Jaguar Health published a July 22, 2026 release on compassionate-use access to liquid oral crofelemer for an EU infant with MVID-related intestinal failure.
Program update flagged a planned FDA NDA filing for MVID in mid-2027.
ESPGHAN 2026 data cited PS reductions up to 48% in an MVID patient, up to 40% in two SBS-IF patients, with no significant abnormalities.
